BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
Marks remarkable acceleration in innovation using AI technology
Pharma powerhouse names Cecile Guegan interim finance chief
The double-blind, dose-finding ZUPREME-1 trial enrolled 485 adults with overweight or obesity
The study enrolled 639 patients, nearly 80% of whom had previously received a covalent BTK inhibitor
Despite the disruption, the company stressed that “our core business operations are not impacted and remain up and running.
The company said Wegovy hit its first one million prescriptions within 12 weeks of availability
The campaign places renewed focus on a disease that remains incurable despite major scientific advances
Subscribe To Our Newsletter & Stay Updated